Veru Inc. (VERU)
NASDAQ (CM) NASDAQ (CM) Primary 
Veru Inc. (VERU) Q4 2025 Earnings Call Transcript
Veru Inc. (VERU) Q4 2025 Earnings Call Transcript
Veru Announces Novel Modified-Release Oral Formulation for Enobosarm
VERU unveils a novel modified-release oral enobosarm to enhance fat loss while preserving lean mass in chronic weight loss management.
Veru Inc. (VERU) Q3 2025 Earnings Call Transcript
Veru Inc. (NASDAQ:VERU ) Q3 2025 Earnings Call August 12, 2025 8:00 AM ET Company Participants K. Gary Barnette - Chief Scientific Officer Michael J.
Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom
Veru Inc. has pivoted to focus on preventing lean mass reduction in patients using GLP-1 agonists, leveraging its lead asset, enobosarm. A Phase 2b trial showed that a 3mg dose of Enobosarm reduces lean mass loss by 99%, preserves physical function, and enhances selective fat loss when combined with semaglutide (Wegovy). VERU's lean balance sheet, with $20 million in cash and no debt, positions it favorably to take advantage of near-term catalysts.
Veru Inc. (VERU) Q2 2025 Earnings Call Transcript
Veru Inc. (NASDAQ:VERU ) Q2 2025 Results Conference Call May 8, 2025 8:00 AM ET Company Participants Sam Fisch - Executive Director, Investor Relations and Corporate Communications Mitchell Steiner - Chairman, President and Chief Executive Officer Michele Greco - Chief Financial Officer and Chief Administrative Officer Gary Barnette - Chief Scientific Officer Conference Call Participants Anthea Li - Jefferies Gary Nachman - Raymond James William Wood - B. Riley Securities Leland Gershell - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to Veru Inc.'s Investor Conference Call.
Down -9.23% in 4 Weeks, Here's Why Veru (VERU) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Veru (VERU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Veru Inc (VERU) Q1 2025 Earnings Call Transcript
Veru Inc (NASDAQ:VERU ) Q1 2025 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Sam Fisch - Executive Director, Investor Relations and Corporate Communications. Mitchell Steiner - Chairman, Chief Executive Officer and President Michelle Greco - CFO and CAO Gary Barnette - Chief Scientific Officer Conference Call Participants William Wood - B.
Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough
Veru Inc. VERU stock is plummeting on Monday after the company released topline results from the Phase 2b QUALITY clinical study of enobosarm for weight reduction.
What Makes Veru Inc. (VERU) a Strong Momentum Stock: Buy Now?
Does Veru Inc. (VERU) have what it takes to be a top stock pick for momentum investors? Let's find out.
Veru Inc. (VERU) Reports Q4 Loss, Tops Revenue Estimates
Veru Inc. (VERU) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.16 per share a year ago.
Veru Inc. (VERU) Q3 2024 Earnings Call Transcript
Veru Inc. (NASDAQ:VERU ) Q3 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Sam Fisch - Investor Relations & Corporate Communications Mitchell Steiner - Chief Executive Officer Michele Greco - Chief Financial Officer Gary Barnette - Chief Scientific Officer Conference Call Participants Dennis Ding - Jefferies William Wood - B. Riley Securities Gary Nachman - Raymond James Leland Gershell - Oppenheimer Yi Chen - H.C.
Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates
Veru Inc. (VERU) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.13 per share a year ago.
